Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen

Fabrice Journé; Virginie Durbecq; Benjamin Haibe‐Kains; Carole Chaboteaux; G. Rouas; Guy Laurent; Denis Larsimont; M. Piccart; J.J. Body; Christos Sotiriou

doi:10.1016/s1359-6349(08)70534-2

Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen

Identifier:nobleid.org/w1/20260515/4BB652AF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/4BB652AF.svg?ark=w1%2F20260515%2F4BB652AF)](https://nobleid.org/work/w1/20260515/4BB652AF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen

Identifier:nobleid.org/w1/20260515/4BB652AF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/4BB652AF.svg?ark=w1%2F20260515%2F4BB652AF)](https://nobleid.org/work/w1/20260515/4BB652AF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work